CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 88 enrolled
Drug / intervention
[11C]raclopride +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02020408
NCT02020408Phase 4Completed

Monoamine Contributions to Neurocircuitry in Eating Disorders

University of California, San Diego·interventional·Posted Dec 24, 2013·Updated Apr 27, 2020

In Brief

A Phase 4 clinical trial evaluating [11C]raclopride, [11C]DASB, and 1 other intervention for Eating Disorder. Completed, enrolled 88 participants across 1 site.

Detailed Summary

This study will use brain imaging technologies to measure several neurotransmitters (serotonin and dopamine) that contribute to our abilities to respond to reward or inhibit our impulses, and which are known to be altered in the brain of people with anorexia nervosa (AN) and bulimia nervosa (BN). Because palatable food stimulates dopamine secretion, we propose to use a challenge with brain imaging that will stimulate dopamine release which we hypothesize will generate anxiety rather than pleasure in AN, and will help explain why AN restrict eating in order to reduce anxiety. This study will help to understand the unique puzzling symptoms in eating disorders and contribute to finding better methods for identifying effective treatments for these often relapsing and sometimes chronic disorders.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEating Disorder
CountriesUnited States

Timeline

Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedDec 24, 2013
Enrollment StartMay 1, 2011
Primary CompletionDec 31, 2017
TodayJul 2, 2026
Enrollment to primary: 6.7 yearsPosted 12.5 years ago

Interventions

[11C]raclopridedrug

1.\[11C\]raclopride -The change (Δ) in BPND (the difference between the \[11C\]raclopride BPND at baseline and post-AMPH treatment normalized to the baseline BPND

[11C]DASBdrug

BPND of \[11C\]DASB.

amphetaminedrug

The change (Δ) in BPND (the difference between the \[11C\]raclopride BPND at baseline and post-AMPH treatment normalized to the baseline BPND.